U.S. FDA approves Novartis Leqvio to lower cholestrol

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1

Piramal Pharma takes a minority stake in Yapan Bio

The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn

Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy

Novartis collaborates with BeiGene to strengthen immunotherapy pipeline

Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis

Moderna says Covid-19 booster dose works against Omicron in lab study

Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold

Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant

The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research

Six benefits of Cloud Computing in the pharma industry

Syngene extends contract with Amgen till 2026

Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects

Novartis announces next-generation CAR-T platform, T Charge

T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies

Aerogen partners with CanSinoBIO for aerosolised Covid-19 vaccine

The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.